Tecentriq, Kesimpta lead latest SMC decisions
13th July 2021 Uncategorised 0SMC was unable to accept Pfizer’s Vyndaqel for use in patients with transthyretin amyloidosis
More: Tecentriq, Kesimpta lead latest SMC decisions
Source: News
SMC was unable to accept Pfizer’s Vyndaqel for use in patients with transthyretin amyloidosis
More: Tecentriq, Kesimpta lead latest SMC decisions
Source: News
© 1994 - 2026 B.M. Pharmaceuticals